Spartina Biotechnologies

Leadership

Executive Leadership

Paul Laur
CEO & Co-Founder

Paul has worked in biotech since 2008 when he was the founder and CEO of Eldorado Biofuels where he met Dr. Sayre as a Principal Investigator for the National Association for Advanced Biofuels and Bioproducts consortium. Paul also founded Santa Fe Cider Company, was Director of Operations at Anguilla Rums, and Director of Corporate Development at Pebble Labs. Paul holds a USCG Master Mariner’s license and spent over twenty years sailing around the world on ocean racing sailboats and cargo ships. He completed his master’s degree at St. John’s College in Santa Fe, NM, and his B.S. at California Maritime Academy. He currently serves on the Boards of the NM Biotechnology and Biomedical Association, Ponderous Panda Capital Corporation, and the Pecos River Resolution Corporation.

Keara Sauber
President

Keara Sauber, a serial entrepreneur, began her first business in financial services in college and continues today in ventures from tech, health, and finance.

Starting in sales and marketing at GlaxoSmithKline, she spent half a decade in a prestigious leadership program that rotated her through every area of the company. Her innate curiosity and leadership drive led her to win multiple awards while at GSK. Keara then served as an operating partner and managed physicians, sales, risk mitigation, planning, and end-to-end facility needs for a sleep lab. During this tenure, she and her partner worked to successfully change Federal and State legislation regarding medical criteria in the transportation sector. 

Keara led the acquisitions team at a private equity company and completed more than 23 asset purchase agreements.  She was recruited to a specialty lender backed by Goldman Sachs as Vice President where her syndicate platform originated more than $500 million dollars to date.

Her consulting work includes expertise in pulmonary, cardiology, metabolic health, infectious diseases, urology, dermatology, viral diseases, and bioremediation.  She has served as the President of a biological testing company from Los Alamos, NM, and has built proprietary systems and apps for fintech projects.

Keara was awarded The U.S. Department of State Global Entrepreneurship Program (GEP) Award.

Keara holds dual Bachelor of Science degrees from Seton Hall University in Marketing with a minor in finance and a Bachelor of Science in Management with a minor in psychology.

Science Leadership

Tatiana Vinogradova-Shah, Ph.D.
Research Director

Tatiana received her Ph.D. in cell biology from the Institute of Experimental Cardiology, Cardiology Research Center in Moscow, Russia and completed postdoc studies in cell and molecular biology at Vanderbilt University and Wadsworth Center. Prior joining Spartina Biotech company, Tanya worked three years as Vice President for Research at MermaidBio division of Pebble Labs, where she led the research for development of anti-viral and anti-bacterial biotherapeutics to combat infectious diseases in aquaculture.

Her expertise lies in molecular biology, molecular cloning, and genetics, bacterial genome editing. She also has expertise in RNAi (dsRNA/siRNA/asRNA) applications for gene silencing in bacteria, invertebrates, plants and mammalian cell cultures. Tatiana is author of 12 scientific papers and 7 patents (issued and pending).

Elena Sineva, Ph.D.
Senior Research Scientist

Elena received her Ph.D. in Biochemistry from Bar Ilan University. She completed postdocs at Penn State University and UTMB in yeast gene repair and has served as a scientist and research professor at Rutgers University, UC San Diego and at Penn State University prior to coming to Los Alamos, New Mexico where she served as a Senior Research Scientist for Pebble Labs.

Elena has expertise in molecular and general microbiology, molecular cloning and genetics, site-directed, random and saturation mutagenesis, bacterial genome editing, yeast genetics, and sequencing. She also has expertise in RNA in vitro transcription; RNA-DNA EMSA, footprinting and labeling; and RTqPCR Northern blots.

Wataru Nishima, Ph.D.
Bioformatics Scientist

Wataru has investigated several biological systems including T4 phage infection, multi-drug resistance, Ebola/Zika virus prefusion-fusion transition, cytokine/enzyme design, mRNA-tRNA translocation on the ribosome, using statistical/sequence analysis, computer simulation, computational protein design approaches. He also developed methodologies to characterize protein/glycan conformational changes. One of the challenging projects he had worked is an MD simulation of GATA4 human gene consisting of 1 billion atoms with massively parallel processing (>500,000 CPU cores ≅ whole nodes of Trinity supercomputer) at Los Alamos National Laboratory. He holds a Ph.D. in Bioinformatics from the University of Tokyo.

 
Todd Buck, Ph.D.
Patent Counsel - Mintz

Dr. Buck is a seasoned patent prosecutor and portfolio manager for Mintz. His practice includes portfolio strategies, preparing and prosecuting patent applications & licensing transactions. He represents pharma and biotech clients in IP & FDA laws.

Scientific Advisory Board

Stephen Hedrick, Ph.D.
Professor

Stephen Hedrick is a molecular biologist with a wealth of experience in the field of immunology and a unique insight into the understanding of how immune systems in organisms evolve in concert with pathogens.

Stephen received his Ph.D. from the University of California and conducted his postdoctoral studies at the National Institutes of Health (NIH). He is the Distinguished Professor, Chancellor’s Associates Chair in Biological Sciences at UC San Diego where he has been for more than 30 years. His research work focuses on the regulation of the immune system including cell death, signal transduction, and evolution.

Robert Malone, MD
CEO & Principal Consultant

Dr. Malone is a specialist in clinical research, medical affairs, regulatory affairs, project management, proposal management, vaccines, and biodefense.  He has been involved in developing, designing, and providing oversight for forty phase-1 clinical trials, twenty phase-2 clinical trials, and five phase-3 clinical trials as Medical Director or principal investigator for vaccine-focused Clinical Research Organizations. He has served as Chief Medical Officer, CEO and Medical Director for multiple Pharmaceutical and Vaccine projects and programs. He earned his medical degree from Northwestern University Medical School and graduated with distinction from Harvard Medical School in a Global Clinical Scholars Research Program. Dr. Malone also completed an internship and research fellowship at UC Davis Medical Center in California.

John (Jack) Lewin, M.D.
Board Member

John C. (Jack) Lewin, MD is Principal and Founder of Lewin and Associates LLC of New York City, and is also Chairman of the National Coalition on Health (NCHC) of Washington DC; and CEO of Convergent Health Systems. Dr. Lewin is an internationally recognized expert in promoting healthy populations and is a strong proponent of a more efficient, effective, and sustainable healthcare system that provides access to high-quality care for all. He has advised two Presidents of the United States as part of a rewarding career in health care, public health, and public policy.

 

Richard Sayre, Ph.D.
Board Member

Dr. Sayre completed his Ph.D. at the University of Iowa on photosynthetic carbon metabolism He was an academic professor in Biochemistry and Plant Biology at Ohio State University and Chairman of Plant Cellular and Molecular Biology. Dr. joined the Los Alamos National Laboratory as a Senior Research Scientist – 6 prior to co-founding Pebble Labs (RNAi – based pathogen control) and Trait Biosciences (Cannabis biotechnology) while serving both companies as Chief Scientific Officer prior to joining Spartina Biotechnologies. Dr. Sayre has authored more than 140 peer-reviewed research publications, 350 invited presentations, and over 60 patents (issued and pending).

Board of Directors

Paul Laur
CEO & Co-Founder
Steve Kiziuk
Board Member
Steve Buehlow
Board Member